Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

ResMed Earnings Call: Key Takeaways

ResMed delivered strong FY2026 results with 10% revenue growth and introduced FY2027 guidance, balancing core sleep growth against a $75 million headwind from the Astral field safety action.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthAmericas sleep devices up 8%; Rest of World sleep devices up 13%.
Mgmt ConfidenceHigh confidence in 2030 strategy and high-single-digit long-term revenue growth.
Demand VisibilityStrong top-of-funnel demand from GLP-1 awareness and wearable sleep tracking.
Margin TrendsGross margin 62.3%, up 90bps YoY; FY2027 low double-digit expansion expected.
Op. LeverageOperating margin 35.2%; 180bps expansion in FY2026; slight expansion guided FY2027.
Pricing PowerImplementing very modest price increases to offset inflation in components and freight.
Vol vs PriceGrowth is predominantly volume-led; price increases described as very modest.
Segment GrowthMasks grew 10% in Americas; Residential Care Software expected high-single-digit growth.
New ClientsOura partnership drove 13,000 users to ResMed; 75% identified as undiagnosed.
Capex & DebtAcquired Noctrix; divesting MatrixCare; $160M-$180M Capex; $1.5B share buyback planned.
RegulatoryAstral field safety corrective action; $42M provision taken for expected costs.
CommentaryFocusing on 'active portfolio management' by divesting non-core assets like MatrixCare.
New LaunchesAirSense 11 China launch; AirCurve 11 ST/STA; AirFit F40 fabric mask.

Growth

FY2026 revenue grew 10% to $4.7 billion; non-GAAP EPS rose 17%.

Outlook

FY2027 revenue guidance of $5.75B-$5.85B; returning over $1.85B to shareholders via buybacks and dividends.

Risks

Astral field safety notice creates a $75 million revenue headwind and 15-cent EPS drag in FY2027.

Source

The company's earnings call, NYSE: RMD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Resmed Inc: key numbers

Share price
$238.19Close, Nov 16
Market cap
$33.5B
Shares outstanding
140.66MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Resmed Inc

All →
6:07 AM ET Form 4
Insider Selling

Resmed Chairman and CEO Michael J. Farrell Sells $1.18M of Stock

Michael J. Farrell, Chairman and CEO, sold 4,993 shares of Resmed Inc at $235.35 a share, worth $1.18M in total on Nov 9, 2026. Shares held after the trade: 479,803 (-1.0%).

Value
$1.18M
Shares
4,993
Price
$235.35
Role
Chairman and CEO
Holding change
-1.0%
Trade date
Nov 9, 2026
6:02 AM ET 10-Q
Financial Results ▶ Call

Resmed Q1 2026 Results: Net Income $418M, Up 20.0% YoY

ResMed Inc. reported a net revenue increase to $1.41 billion for the quarter ended September 30, 2026, compared to $1.34 billion in the prior year, driven by Sleep and Breathing Health products. Net income rose to $418.4 million, significantly aided by a $61.8 million gain from the divestment of subsidiaries.

Key figure
Net income $418M · +20.0% YoY
4:07 PM ET 8-K
Financial Results

Resmed Financial Results

ResMed reported Q1 fiscal year 2027 revenue of $1.4 billion, a 6% increase driven by global demand for sleep and breathing health solutions. The company returned over $1 billion to shareholders through dividends and share repurchases during the quarter, supported by strong free cash flow and the divestiture of MatrixCare.

Term
Q1 2027

“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business. Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%.”

Mick Farrell, Resmed’s Chairman and CEO

“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”

Mick Farrell, Resmed’s Chairman and CEO
3:40 PM ET Form 4
Insider Selling

Resmed Global General Counsel Michael J. Rider Sells $102K of Stock

Michael J. Rider, Global General Counsel, sold 400 shares of Resmed Inc at $255.00 a share, worth $102K in total on Oct 23, 2026. Shares held after the trade: 12,318 (-3.1%).

Value
$102K
Shares
400
Price
$255.00
Role
Global General Counsel
Holding change
-3.1%
Trade date
Oct 23, 2026
5:32 PM ET Form 4
Insider Selling

Resmed Chairman and CEO Michael J. Farrell Sells $1.13M of Stock

Michael J. Farrell, Chairman and CEO, sold 4,991 shares of Resmed Inc at $226.33 a share, worth $1.13M in total on Oct 7, 2026. Shares held after the trade: 479,803 (-1.0%).

Value
$1.13M
Shares
4,991
Price
$226.33
Role
Chairman and CEO
Holding change
-1.0%
Trade date
Oct 7, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.